ALVO
NASDAQ · Biotechnology
Alvotech Sa
$4.55
-0.12 (-2.57%)
Financial Highlights (FY 2026)
Revenue
842.95M
Net Income
39.95M
Gross Margin
60.0%
Profit Margin
4.7%
Rev Growth
+90.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 60.0% | 60.0% | 56.3% | 56.3% |
| Operating Margin | 17.6% | 15.9% | 29.6% | 24.9% |
| Profit Margin | 4.7% | 4.5% | 19.5% | 23.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 842.95M | 442.21M | 133.98M | 123.74M |
| Gross Profit | 505.77M | 265.33M | 75.43M | 69.66M |
| Operating Income | 148.70M | 70.21M | 39.62M | 30.84M |
| Net Income | 39.95M | 18.86M | 26.13M | 29.17M |
| Gross Margin | 60.0% | 60.0% | 56.3% | 56.3% |
| Operating Margin | 17.6% | 15.9% | 29.6% | 24.9% |
| Profit Margin | 4.7% | 4.5% | 19.5% | 23.6% |
| Rev Growth | +90.6% | +90.6% | +20.0% | +10.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | — | — | 315.40M | 394.86M |
| Total Equity | — | — | 787.29M | 748.59M |
| D/E Ratio | — | — | 0.40 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 171.44M | 85.44M | 43.53M | 37.02M |
| Free Cash Flow | — | — | 33.36M | 27.22M |